Figure S4 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

Kristina Drizyte‐Miller; Lars D. Engstrom; Jeffrey A. Klomp; Clint A. Stalnecker; Addison G. Stamey; Khalilah E. Taylor; Mallory K. Roach; Ryan Robb; Laura Waters; Andrew Calinisan; Seamus Degan; Wen-Hsuan Chang; Xousaen M. Helu; David Nguyen; Elisa Baldelli; Mariaelena Pierobon; Emanuel F. Petricoin; David M. Briere; Jill Hallin; James G. Christensen; Kirsten L. Bryant; Adrienne D. Cox; Peter Olson; Channing J. Der

doi:10.1158/0008-5472.30125934

Key Points

Combination treatment of PRMT5 and KRAS inhibitors shows effectiveness against pancreatic cancer.
Results indicate that the treatment could be beneficial for cases with MTAP deletions.
The study involved in vivo analyses to assess the treatment strategy's impact.
Findings highlight the potential of using combined therapies in aggressive cancer types.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

In vivo analysis demonstrates that PRMT5i and KRASi combination treatment effectively targets pancreatic cancer, suggesting potential efficacy in MTAP-deleted cases.

Abstract

Figure S4 shows PRMT5i and KRASi combination treatment analysis in vivo.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Drizyte‐Miller et al. (2025) studied this question.

synapsesocial.com/papers/68d4508931b076d99fa5887f https://doi.org/10.1158/0008-5472.30125934

View Full Paper

Ask AI

Bookmark

Share

Figure S4 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Figure S4 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading